Figures & data
Table 1 Baseline data of all patients and groups according to the type of immunomodulatory treatment (IMT)
Figure 1 Distribution of EDSS score at baseline in groups with different immunomodulatory agents.
![Figure 1 Distribution of EDSS score at baseline in groups with different immunomodulatory agents.](/cms/asset/d3f6682a-e8d5-4e4b-9363-f28c6bb5f5b7/dndt_a_36771_f0001_b.jpg)
Figure 2 Effect of treatment on relapse numbers in the groups according to the type of immunomodulatory treatment (IMT).
![Figure 2 Effect of treatment on relapse numbers in the groups according to the type of immunomodulatory treatment (IMT).](/cms/asset/0a198bd7-f8c3-49f3-9922-3487c4ea30f4/dndt_a_36771_f0002_b.jpg)
Table 2 Effect of treatment on EDSS progression in patient subgroups according to the length of continuous immunomodulatory treatment (IMT)
Figure 3 Sustained efficacy of longer than 6 years’ immunomodulatory treatment on disability.
![Figure 3 Sustained efficacy of longer than 6 years’ immunomodulatory treatment on disability.](/cms/asset/d0dd66a5-b9a7-497c-86d3-8d4fcca3b6e0/dndt_a_36771_f0003_b.jpg)
Table 3 Baseline data of patients and treatment response in the groups according to clinical presentation at onset of multiple sclerosis (MS)
Table 4 Long-term effect of immunomodulatory treatment (IMT) on EDSS change in the groups according to short-term response to IMT by relapse numbers
Table 5 Incidences of side effects of immunomodulatory drugs